FRANKFURT, Germany (AP) — Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

The Darmstadt-based company said Thursday that its net profit rose to €272 million ($355 million), from €133 million in the same quarter the year before. Revenues rose 8 percent to €2.83 billion.

Recommended Stories

Don’t blame the pro-life movement for Republican losses

First round of November Social Security payments goes out in 9 days

I stared down the ‘Blind Sheikh’ for the FBI. What’s happening today is far more dangerous